Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer
The MTD was carboplatin AUC 2 + gemcitabine 600 mg/m<sup>2</sup> on D1 and 8 with Mif 300 mg D-1 and D1 with pegylated G-CSF administered on day 9 of a 21-day cycle.
Authors
- Gabrielle M. Baker (ORCID: https://orcid.org/0000-0002-9213-0317)
- Rita Nanda (ORCID: https://orcid.org/0000-0001-5248-0876)
- Suzanne Daniela Conzen (ORCID: https://orcid.org/0000-0003-1750-5868)
- Poornima Saha (ORCID: https://orcid.org/0009-0005-6609-7188)
- Lauren Olalde
- Theodore Karrison (ORCID: https://orcid.org/0009-0009-8641-5111)
- Erica Stringer-Reasor (ORCID: https://orcid.org/0000-0002-1862-3367)
- Ricardo R. Lastra (ORCID: https://orcid.org/0000-0003-0691-5685)
- Gini F. Fleming (ORCID: https://orcid.org/0000-0003-2845-4023)
- Masha Kocherginsky (ORCID: https://orcid.org/0000-0002-3510-9562)
- Philip C. Hoffman
- Olwen Hahn
- Ernst Lenygel
- Elizabeth Mokrzycki
Institutions
- Northwestern University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Chicago (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1007/s10549-025-07783-7
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00